Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates.
The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth greater than 30% from the previous year, compared to the previous suggestion of greater than 25%.
Shares of Insulet fell more than 10% to $149 apiece before the market opened today.
The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $95 million. That equals $1.37 per share on sales of $801.7 million for the three months ended June 30, 2026.
Insulet more than quadrupled its profits on a sales increase of 23.5%.
Adjusted to exclude one-time items, earnings per share came in at $1.66. That landed 21¢ ahead of expectations on Wall Street. Sales also topped the forecast as experts projected $787.4 million in revenue.
Highlights in the quarter included the launch of a new Omnipod 5 algorithm alongside enhanced compatibility with Abbott sensors, as well as new data supporting its next-generation Omnipod 6 system and fully closed-loop automated insulin delivery systems.
However, the company’s quarter also included another Omnipod safety notice in May, with this one related to a manufacturing issue that could result in insulin under-delivery with the affected current-generation Omnipod 5, previous-generation Omnipod Dash or the prior Omnipod Insulin Management System (Eros). Insulet said the scope of this action reaches approximately 7 million pods. The company instructs users to identify affected devices and discontinue use. This issue was separate from the March recall that affected certain Omnipod 5 lots. The FDA identified that recall as its most serious type last month, with 476 medical device reports, 29 serious injuries and no deaths associated with the previous issue.
Ashley McEvoy, Insulet president and CEO, said:
“We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow, reflecting the strength of the Omnipod platform. While we are updating our outlook to reflect what we’re learning as we scale in type 2, our conviction in the long-term opportunity remains unchanged. We remain focused on converting those insights into action, further strengthening execution and positioning the business for durable, profitable growth.”
